SE443716B - Sett att framstella en farmaceutisk beredning for inhibering av blodplettsaggregation innehallande prostacyklin eller dihydroprostacyklin och en fosfodiesterasinhibitor - Google Patents

Sett att framstella en farmaceutisk beredning for inhibering av blodplettsaggregation innehallande prostacyklin eller dihydroprostacyklin och en fosfodiesterasinhibitor

Info

Publication number
SE443716B
SE443716B SE7805707A SE7805707A SE443716B SE 443716 B SE443716 B SE 443716B SE 7805707 A SE7805707 A SE 7805707A SE 7805707 A SE7805707 A SE 7805707A SE 443716 B SE443716 B SE 443716B
Authority
SE
Sweden
Prior art keywords
pyrazolo
pyridine
ethyl
pharmaceutically acceptable
phosphodiesterase inhibitor
Prior art date
Application number
SE7805707A
Other languages
English (en)
Swedish (sv)
Other versions
SE7805707L (sv
Inventor
P Cuatrecasas
S Moncada
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of SE7805707L publication Critical patent/SE7805707L/xx
Publication of SE443716B publication Critical patent/SE443716B/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SE7805707A 1977-05-20 1978-05-18 Sett att framstella en farmaceutisk beredning for inhibering av blodplettsaggregation innehallande prostacyklin eller dihydroprostacyklin och en fosfodiesterasinhibitor SE443716B (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79900777A 1977-05-20 1977-05-20
GB3526177 1977-08-23

Publications (2)

Publication Number Publication Date
SE7805707L SE7805707L (sv) 1978-11-21
SE443716B true SE443716B (sv) 1986-03-10

Family

ID=26262642

Family Applications (1)

Application Number Title Priority Date Filing Date
SE7805707A SE443716B (sv) 1977-05-20 1978-05-18 Sett att framstella en farmaceutisk beredning for inhibering av blodplettsaggregation innehallande prostacyklin eller dihydroprostacyklin och en fosfodiesterasinhibitor

Country Status (8)

Country Link
JP (1) JPS542335A (fr)
CH (1) CH643458A5 (fr)
DE (1) DE2821737A1 (fr)
FR (1) FR2390964A1 (fr)
HU (1) HU180548B (fr)
IT (1) IT1105506B (fr)
NL (1) NL7805402A (fr)
SE (1) SE443716B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA787353B (en) * 1978-05-17 1980-08-27 Wellcome Found Pharmaceutical formulations
DE3526362A1 (de) * 1985-07-19 1987-01-22 Schering Ag Prostacycline, ihre analoga oder prostaglandine und thromboxanantagonisten zur behandlung von thrombotischen und thromboembolischen krankheitsbildern
EP0299698B1 (fr) * 1987-07-14 1992-09-09 Sankyo Company Limited Composition pour former des articles médicaux antithrombotiques

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2235678A1 (en) * 1973-07-02 1975-01-31 Merck & Co Inc Topical antipsoriasis agents - contg. prostaglandin E1 or E2

Also Published As

Publication number Publication date
JPS542335A (en) 1979-01-09
DE2821737A1 (de) 1978-11-30
SE7805707L (sv) 1978-11-21
NL7805402A (nl) 1978-11-22
FR2390964A1 (fr) 1978-12-15
CH643458A5 (en) 1984-06-15
FR2390964B1 (fr) 1980-07-11
IT7849485A0 (it) 1978-05-22
IT1105506B (it) 1985-11-04
DE2821737C2 (fr) 1988-05-19
HU180548B (en) 1983-03-28

Similar Documents

Publication Publication Date Title
EP1461039B1 (fr) Compositions pharmaceutiques comportant cilostazol et un inhibiteur d'apport d'adenosine
AU776724B2 (en) Use of corticotropin releasing factor antagonists and related compositions
KR101176110B1 (ko) 문맥성 고혈압의 예방 및/또는 치료
US20010041673A1 (en) Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues
JP6014695B2 (ja) 癌および他の疾患または障害の治療のための医薬組成物
CA2450777A1 (fr) Utilisation d'inhibiteurs c-src seuls ou en combinaison avec sti571 pour le traitement de leucemies
Casals‐Stenzel et al. Triazolodiazepines: dissociation of their Paf (platelet activating factor) antagonistic and CNS activity
JPH0367045B2 (fr)
US4337254A (en) Pharmaceutical compositions
SE443716B (sv) Sett att framstella en farmaceutisk beredning for inhibering av blodplettsaggregation innehallande prostacyklin eller dihydroprostacyklin och en fosfodiesterasinhibitor
KR20190085946A (ko) 트리시클릭 유도체 또는 이의 약학적으로 허용 가능한 염을 포함하는 허혈성 급성 신 손상 예방 또는 치료용 약학적 조성물
EP0667349A1 (fr) Antidepresseur
GB1601034A (en) Pharmaceutical compositions
US3987173A (en) Pharmaceutical preparations comprising vincamine alkaloids and dihydroergocristine
KR20200027470A (ko) 다낭성 질환 치료용 릭시밥탄 제제
ES2260061T3 (es) Composiciones farmaceuticas para trastornos relacionados con la alimentacion.
EP0011828A1 (fr) Mélanges pharmaceutiques contenant des dérivés de l'hydantoine, compositions pharmaceutiques contenant ces mélanges et procédés pour leur préparation
EP0338010B1 (fr) Compositions pharmaceutiques pour le traitement des maladies de la peau hyperproliferantes
JPH02142728A (ja) 抗アテローム性動脈硬化症剤及び抗過コレステリン血症剤としてのピラゾロピリジン誘導体
WO2018144791A1 (fr) Combinaison d'inhibiteurs de vps34 et d'inhibiteurs de mtor
AU4281993A (en) Compositions of platelet activating factor antagonists and methods of treating interleukin-2 induced lung injury therewith
MXPA99010735A (en) THE USE OF 1,2,4-TRIAZOLO[1,5-c]PYRIMIDINE HETEROCYCLIC ANALOGUES FOR THE PREPARATION OF MEDICAMENTS USEFUL FOR THE TREATMENT OF CEREBROVASCULAR DISTURBANCES
HU193280B (en) Process for preparing novel hidantane derivatives and compositions comprising the same as active substance

Legal Events

Date Code Title Description
NUG Patent has lapsed

Ref document number: 7805707-2

Effective date: 19890525

Format of ref document f/p: F